COMPANY

Evofem Biosciences

HQ: San Diego, CA source · evofem.com ↗ · West Coast

Keywords: women's health bacterial vaginosis Contraception Central Abdominal Bulging Sexually Transmitted Diseases Gonorrhea Chlamydia Chlamydia Trachomatis Infection EVO100 LIPO-202 AMPHORA

Location: San Diego, CA · source · Oct 13, 2026

Profile checked Oct 10, 2026

7Trials (company is sponsor)

Timeline

Oct 15, 2020 Trial start Phase 3: Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection source ↗
Nov 3, 2017 Trial start 2B: Phase 2B/3 Double-blinded Placebo-controlled source ↗
Jul 24, 2017 Trial start III: AMP002 Phase III Contraceptive Study source ↗
Aug 24, 2016 Trial start Phase 1: Duration of Effect of Acidform Gel on Vaginal pH source ↗
2015-06 Trial start Phase 3: Extension Study to Evaluate the Post-Treatment Safety and Duration of Clinical Effect of LIPO-202 source ↗
Apr 9, 2015 Trial start Phase 3: Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat (AbCONTOUR2) source ↗
2011-04 Trial start Phase 3: Study of Contraceptive Efficacy & Safety of Phexxi™ (Previously Known as Amphora) Gel Compared to Conceptrol Vaginal Gel source ↗

Clinical trials (lead sponsor) 7

Record	Title	Phase	Status	Start	Primary completion
NCT04553068	Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection	Phase 3	Completed	Oct 15, 2020	Jul 28, 2022 (actual)
NCT01306331	Study of Contraceptive Efficacy & Safety of Phexxi™ (Previously Known as Amphora) Gel Compared to Conceptrol Vaginal Gel	Phase 3	Completed	2011-04	2014-06 (actual)
NCT02693418	Duration of Effect of Acidform Gel on Vaginal pH	Phase 1	Completed	Aug 24, 2016	Dec 12, 2016 (actual)
NCT03243305	AMP002 Phase III Contraceptive Study	III	Completed	Jul 24, 2017	Nov 29, 2018 (actual)
NCT03107377	Phase 2B/3 Double-blinded Placebo-controlled	2B	Completed	Nov 3, 2017	Aug 22, 2019 (actual)
NCT02483533	Extension Study to Evaluate the Post-Treatment Safety and Duration of Clinical Effect of LIPO-202	Phase 3	Terminated	2015-06	Dec 23, 2015 (actual)
NCT02398188	Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat (AbCONTOUR2)	Phase 3	Completed	Apr 9, 2015	Oct 29, 2015 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

2025-07-02 Raise Private raise (SEC Form D): $925K sold; issuer “Evofem Biosciences, Inc.”. Verified from the SEC filing. SEC filing ↗
2025-04-15 Raise Private raise (SEC Form D): $750K sold of $1.5M offered; issuer “Evofem Biosciences, Inc.”. Verified from the SEC filing. SEC filing ↗